IMVT Immunovant, Inc.: Forward P/S Multiple
Immunovant, Inc. (IMVT) is integrating ESG principles into the development of immunological drugs by optimizing laboratory energy consumption. The company is currently expanding its portfolio of targeted antibodies, accelerating the final stages of clinical trials. This chart of the company's expected P/S reflects the valuation dynamics, where the value serves as the baseline indicator. In the future, the uniqueness of its patented treatments for rare pathologies will provide the issuer with significant pricing power.
Metric breakdowns and analytics for Immunovant Therapeutics (IMVT)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
IMVT - Net Profit|Expected Profit Immunovant, Inc.|IMVT - Price to Earnings Multiple|Projected Price to Earnings Immunovant Corp|IMVT - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Immunovant Therapeutics|IMVT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Immunovant|IMVT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months immunovant.com|IMVT - Earnings per share growth this year|Earnings growth forecast for next year Immunovant, Inc.
- sales and revenue data:
Fundamental company valuation:IMVT (Immunovant)
Forward P/S measures the market value of a business relative to expected sales, allowing an investor to determine the degree of asset overheating and the boundaries of a fair valuation. For Immunovant, Inc. (IMVT), which develops unique antibodies in the rare disease niche, the forward price-to-sales ratio serves as an indicator of how much the market currently prices in future clinical efficacy and patent protection for its therapies.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple kiniksa.com|Price-to-Projected Revenue Ratio Grifols|Forward Price-to-Revenue Multiple Adaptive Biotech (ADPT)|Forward Price-to-Revenue Multiple CLDX (Celldex)|Forward P/S Multiple Aurinia Corp (AUPH)|Price-to-Projected Revenue Ratio BioCryst BCRX|VERA: Market Cap to Projected Revenue|DNTH - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Pharvaris NV|ABCL (AbCellera Biologics Inc) - Forward Price-to-Revenue Multiple|TRML (Tourmaline) - Price-to-Projected Revenue Ratio|PGEN (Precigen, Inc.) - Forward P/S Multiple|Forward P/S Multiple pharming.com|Price-to-Projected Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Projected Revenue|Zenas Biopharma, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio IMNM (Immunome Bio)|GOSS: Forward Price-to-Revenue Multiple|Forward Price to Sales KALV (kalvista.com)|SEPN: Forward P/S Multiple|PVLA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Savara Corp|Market Cap to Projected Revenue RIGL (Rigel Corp)|Forward P/S Multiple ANAB|Forward Price-to-Revenue Multiple astriatx.com ATXS|enGene - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio RAPT Therapeutics Inc. (RAPT)|Aerovate - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple tizianalifesciences.com|Forward Price-to-Revenue Multiple CABA|Price-to-Projected Revenue Ratio VTYX|Forward Price-to-Revenue Multiple THTX (Theratechnologies Inc)|Price to Expected Revenue Ratio AVTX|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Future Price to Revenue|Climb Bio - Forward P/S Multiple|Forward Price to Sales ZURA (Zura Bio Ltd)|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ImageneBio|STTK: Forward Price to Sales|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|Forward Price-to-Revenue Multiple connectbiopharm.com CNTB|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Forward Price-to-Revenue Multiple|Forward Price to Sales XFOR (x4pharma.com)|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX: Forward Price-to-Revenue Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Price-to-Projected Revenue Ratio CALI (calcimedica.com)|Forward P/S Multiple AFMD (Affimed N.V.)|Forward P/S Multiple Allakos Inc ALLK|HOOK - Price-to-Projected Revenue Ratio|IGMS (IGM Biosciences, Inc.) - Market Cap to Projected Revenue|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|OCEA: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
